Cerebrospinal Fluid Proteins Predict Longitudinal Hippocampal Degeneration in Early-stage Dementia of the Alzheimer Type

Objective:Biomarkers are needed to improve the sensitivity and accuracy of diagnosis, and also prognosis, in individuals with early Alzheimer disease (AD). Measures of brain structure and disease-related proteins in the cerebrospinal fluid (CSF) have been proposed as biomarkers, yet relatively little is known about the relationships between such measures. The present study was conducted to assess the relationship between CSF A&bgr; and tau protein levels and longitudinal measures of hippocampal structure in individuals with and without very mild dementia of the Alzheimer type. Design:A single CSF sample and longitudinal magnetic resonance scans were collected. The CSF samples were assayed for tau, phosphorylated tau181 (p-tau181), A&bgr;1-42, and A&bgr;1-40 using an enzyme-linked immunosorbent assay. Large-deformation diffeomorphic metric mapping was used to generate hippocampal surfaces, and a composite hippocampal surface (previously constructed from 86 healthy participants) was used as a structural reference. Patients or Other Participants:Thirteen participants with very mild AD (Clinical Dementia Rating, CDR 0.5) and 11 cognitively normal participants (CDR 0). Intervention:None. Main Outcome Measures:Initial and rate-of-change measures of total hippocampal volume and displacement of the hippocampal surface within zones overlying the CA1, subiculum, and CA2-4+DG cellular subfields, and their correlations with initial CSF measures. Results:Lower CSF &Agr;&bgr;1-42 levels and higher tau/&Agr;&bgr;1-42 and p-tau181/&Agr;&bgr;1-42 ratios were strongly correlated with decreases in hippocampal volume and measures of progressive inward deformations of the CA1 subfield in participants with early AD, but not in cognitively normal participants. Conclusions:Despite the small sample size, we found that &Agr;&bgr;1-42 related and tau-related CSF measures were associated with hippocampal degeneration in individuals with clinically diagnosed early AD and may reflect an association with a common underlying disease mechanism.

[1]  Kaj Blennow,et al.  Cerebrospinal fluid protein biomarkers for Alzheimer’s disease , 2004, NeuroRX.

[2]  A. Dale,et al.  Brain atrophy in healthy aging is related to CSF levels of Aβ1-42. , 2010, Cerebral cortex.

[3]  Michael W. Weiner,et al.  Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans , 2010, Neurobiology of Aging.

[4]  C R Jack,et al.  Serial MRI and CSF biomarkers in normal aging, MCI, and AD , 2010, Neurology.

[5]  Frederik Barkhof,et al.  Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study , 2010, Neurobiology of Aging.

[6]  A. Dale,et al.  CSF Biomarkers in Prediction of Cerebral and Clinical Change in Mild Cognitive Impairment and Alzheimer's Disease , 2010, The Journal of Neuroscience.

[7]  K. Blennow,et al.  Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. , 2010, Archives of neurology.

[8]  A. Fagan,et al.  Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease , 2009, EMBO molecular medicine.

[9]  Henrik Zetterberg,et al.  Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease , 2009, PloS one.

[10]  Evan Fletcher,et al.  Spatially localized hippocampal shape analysis in late‐life cognitive decline , 2009, Hippocampus.

[11]  Lei Wang,et al.  Fully‐automated, multi‐stage hippocampus mapping in very mild Alzheimer disease , 2009, Hippocampus.

[12]  Michael Weiner,et al.  Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls , 2009, NeuroImage.

[13]  Norbert Schuff,et al.  Alzheimer’s Disease Neuroimaging Initiative: A one-year follow up study using Tensor-Based Morphometry correlating degenerative rates, biomarkers and cognition , 2009 .

[14]  Bradley T. Hyman,et al.  Tau pathophysiology in neurodegeneration: a tangled issue , 2009, Trends in Neurosciences.

[15]  A. Fagan,et al.  Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly , 2009, Annals of neurology.

[16]  C. Jack,et al.  MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers , 2008, Brain : a journal of neurology.

[17]  Rossana Ganzola,et al.  Mapping local hippocampal changes in Alzheimer's disease and normal ageing with MRI at 3 Tesla. , 2008, Brain : a journal of neurology.

[18]  K. Blennow,et al.  Increasing CSF phospho-tau levels during cognitive decline and progression to dementia , 2008, Neurobiology of Aging.

[19]  I. Sokal,et al.  CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment , 2007, Neurology.

[20]  Paul M. Thompson,et al.  Hippocampal shape analysis in Alzheimer’s disease: A population-based study , 2007, NeuroImage.

[21]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[22]  Chunyu Wang,et al.  {gamma}-Secretase Substrate Concentration Modulates the Abeta42/Abeta40 Ratio: IMPLICATIONS FOR ALZHEIMER DISEASE. , 2007, The Journal of biological chemistry.

[23]  M. Goedert,et al.  A Century of Alzheimer's Disease , 2006, Science.

[24]  Anders M. Dale,et al.  An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest , 2006, NeuroImage.

[25]  Kiralee M. Hayashi,et al.  Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. , 2006, Archives of neurology.

[26]  B. Reisberg,et al.  Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment , 2006, Neurobiology of Aging.

[27]  Michael I. Miller,et al.  Abnormalities of hippocampal surface structure in very mild dementia of the Alzheimer type , 2006, NeuroImage.

[28]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[29]  A. Toga,et al.  Three-dimensional patterns of hippocampal atrophy in mild cognitive impairment. , 2006, Archives of neurology.

[30]  Alan C. Evans,et al.  Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. , 2005, Archives of neurology.

[31]  Michael I. Miller,et al.  Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly , 2005, NeuroImage.

[32]  R. Buckner,et al.  Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD , 2005, Neurology.

[33]  Alain Trouvé,et al.  Computing Large Deformation Metric Mappings via Geodesic Flows of Diffeomorphisms , 2005, International Journal of Computer Vision.

[34]  Abraham Z. Snyder,et al.  A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume , 2004, NeuroImage.

[35]  Michael I. Miller,et al.  Changes in hippocampal volume and shape across time distinguish dementia of the Alzheimer type from healthy aging☆ , 2003, NeuroImage.

[36]  D. Holtzman,et al.  In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life , 2003, The Journal of Neuroscience.

[37]  Kaj Blennow,et al.  Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients , 2003, Neuroscience Letters.

[38]  J. Price,et al.  Mild cognitive impairment represents early-stage Alzheimer disease. , 2001, Archives of neurology.

[39]  S. Joshi,et al.  Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus , 2000, Neurology.

[40]  C. Jack,et al.  Rates of hippocampal atrophy correlate with change in clinical status in aging and AD , 2000, Neurology.

[41]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[42]  J. Wegiel,et al.  Neuronal and volume loss in CA1 of the hippocampal formation uniquely predicts duration and severity of Alzheimer disease , 1998, Brain Research.

[43]  J. Wegiel,et al.  Neurofibrillary pathology — correlation with hippocampal formation atrophy in Alzheimer disease , 1996, Neurobiology of Aging.

[44]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[45]  P. Lansbury,et al.  The C‐Terminus of the β Protein is Critical in Amyloidogenesis a , 1993 .

[46]  P. Lansbury,et al.  The C-terminus of the beta protein is critical in amyloidogenesis. , 1993, Annals of the New York Academy of Sciences.

[47]  A. Burns.  Clinical diagnosis of Alzheimer's disease , 1991 .

[48]  G. V. Van Hoesen,et al.  The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.

[49]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.